Abstract

IntroductionOutcomes after deep brain stimulation (DBS) therapy are dependent on good surgical placement in the target nucleus and optimized stimulation parameters through multiple programming sessions. This often requires frequent travel to a specialized DBS center, which presents a challenge for those with limited access. Recently, the FDA approved a remote tele-programming solution for DBS. To determine if remote tele-programming of DBS systems is beneficial and useful for Parkinson's Disease (PD) patients, Parkinson's Foundation hosted a survey in collaboration with Abbott Labs. MethodsThe survey was conducted to assess the need for telemedicine among PD patients with DBS and the usability of the telehealth interface for DBS teleprogramming. The survey included two validated instruments: The Effective Accessibility and Accommodation survey (EAA) and the Telehealth Usability Questionnaire (TUQ). Results47 patients completed the EAA and 41 completed the TUQ. Results from the EAA revealed more than a third of PD patients cannot easily get to a clinic for various reasons, and more than a quarter reported difficulty contacting their clinic for advice. Results from the TUQ revealed overall satisfaction with the DBS remote programming telehealth interface and care provided. The majority of respondents reported that remote tele-programming visits are similar in quality to in-person visits. ConclusionThis study provides support for the use of telehealth and tele-programming for DBS management in PD patients. The ability to use remote technologies for care will increase access to DBS and mitigate the disparities that currently prevent access to care.

Highlights

  • Outcomes after deep brain stimulation (DBS) therapy are dependent on good surgical placement in the target nucleus and optimized stimulation parameters through multiple programming sessions

  • 68 Parkinson’s Disease (PD) patients (47 male) with Abbott DBS systems completed the survey from August 4–27, 2021

  • Results from the second subsection of the Effective Accessibility and Accommodation survey (EAA) revealed that 27.6% (n = 13) reported it would be difficult to contact their clinic for advice by endorsing a rating of 1 or 2

Read more

Summary

Introduction

Outcomes after deep brain stimulation (DBS) therapy are dependent on good surgical placement in the target nucleus and optimized stimulation parameters through multiple programming sessions. NeuroSphereTM Virtual Clinic (Abbott Labs), launched in 2021, is the only FDA approved and CE marked platform for remote tele-programming, where clinicians can provide synchronous telemedicine on video and remotely access and program DBS systems. To examine the need for and feasibility of audio-visual remote teleprogramming of DBS systems in PD patients, Parkinson’s Foundation hosted a collaborative survey with Abbott to (1) assess the accessibility to DBS specialists and (2) assess the usability of the telehealth interface for synchronous DBS tele-programming.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call